Final published version, 751 KB, PDF document
Available under license: CC BY: Creative Commons Attribution 4.0 International License
Final published version
Licence: CC BY: Creative Commons Attribution 4.0 International License
Research output: Contribution to Journal/Magazine › Journal article › peer-review
Research output: Contribution to Journal/Magazine › Journal article › peer-review
}
TY - JOUR
T1 - Poly(2-Hydroxyethyl Methacrylate) Hydrogel-Based Microneedles for Metformin Release
AU - Sharma, Manoj
AU - Kap, Özlem
AU - Abdelmohsen, Hend
AU - Ashton, Mark
AU - Harper, Garry
AU - Firlak, Melike
AU - Aaltonen, Jasmine
AU - Bolland, Kerry
AU - Bragg, Ryan
AU - Deeley, Sarah
AU - Francis, Ella
AU - Kazi, Nahin
AU - Mapley, Bethany
AU - Oikonomou, Vasileios
AU - Aljohani, Amal Dhaifallah
AU - Cheneler, David
AU - Kılıç, Volkan
AU - Horzum, Nesrin
AU - Hardy, John
PY - 2023/8/31
Y1 - 2023/8/31
N2 - The release of metformin, a drug used in the treatment of cancer and diabetes, from poly(2-hydroxyethyl methacrylate), pHEMA, hydrogel-based microneedle patches is demonstrated in vitro. Tuning the composition of the pHEMA hydrogels enables preparation of robust microneedle patches with mechanical properties such that they would penetrate skin (insertion force of a single microneedle to be ≈40 N). Swelling experiments conducted at 20, 35, and 60 °C show temperature-dependent degrees of swelling and diffusion kinetics. Drug release from the pHEMA hydrogel-based microneedles is fitted to various models (e.g., zero order, first order, second order). Such pHEMA microneedles have potential application for transdermal delivery of metformin for the treatment of aging, cancer, diabetes, etc.
AB - The release of metformin, a drug used in the treatment of cancer and diabetes, from poly(2-hydroxyethyl methacrylate), pHEMA, hydrogel-based microneedle patches is demonstrated in vitro. Tuning the composition of the pHEMA hydrogels enables preparation of robust microneedle patches with mechanical properties such that they would penetrate skin (insertion force of a single microneedle to be ≈40 N). Swelling experiments conducted at 20, 35, and 60 °C show temperature-dependent degrees of swelling and diffusion kinetics. Drug release from the pHEMA hydrogel-based microneedles is fitted to various models (e.g., zero order, first order, second order). Such pHEMA microneedles have potential application for transdermal delivery of metformin for the treatment of aging, cancer, diabetes, etc.
KW - aging
KW - cancer
KW - diabetes
KW - drug delivery
KW - hydrogels
KW - microneedles
U2 - 10.1002/gch2.202300002
DO - 10.1002/gch2.202300002
M3 - Journal article
C2 - 37635699
VL - 7
SP - 2300002
JO - Global Challenges
JF - Global Challenges
SN - 2056-6646
IS - 8
M1 - 2300002
ER -